Canine ApoA antibody and antigen (recombinant protein)
Diagnostic anti-Canine ApoA antibodies pairs and antigen for animal health (animal Dog/Canine Cardiovascular Disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Companion Animal disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-CAN-ApoA-Ag01 | Canine ApoA | $3090.00 |
GMP-CAN-ApoA-Ab01 | Anti-Canine ApoA mouse monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-ApoA-Ab02 | Anti-Canine ApoA mouse monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-ApoA-Ab03 | Anti-Canine ApoA human monoclonal antibody (mAb) | $3090.00 |
GMP-CAN-ApoA-Ab04 | Anti-Canine ApoA human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-CAN-ApoA-Ag01 |
Product Name | Canine ApoA |
Target/Biomarker | Canine ApoA |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Canine ApoA antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in ApoA level test of animal Dog/Canine with Cardiovascular Disease. |
Tag | His | Reconized/Reactive Specics | Canine ApoA |
Product description | Recombinant Canine ApoA protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-CAN-ApoA-Ab01,GMP-CAN-ApoA-Ab02 |
Target/Biomarker | Canine ApoA |
Product Name | Anti-Canine ApoA mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Canine ApoA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine ApoA antibodies in Canine ApoA level test of animal Dog/Canine with Cardiovascular Disease. |
Product description | Anti-Canine ApoA mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine ApoA antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-CAN-ApoA-Ab03,GMP-CAN-ApoA-Ab04 |
Target/Biomarker | Canine ApoA |
Product Name | Anti-Canine ApoA human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Canine ApoA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Canine ApoA antibodies in Canine ApoA level test of animal Dog/Canine with Cardiovascular Disease. |
Product description | Anti-Canine ApoA mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Canine ApoA, or Canine Apolipoprotein A, represents a sophisticated facet of the canine physiological landscape. Within the intricate tapestry of a dog's biochemistry, this protein takes on a pivotal role, influencing lipid metabolism and cardiovascular health in profound ways.
At its core, Canine ApoA is a member of the apolipoprotein family, a group of proteins recognized for their capacity to modulate lipid transport through the circulatory system. Apolipoproteins are like molecular shepherds, guiding lipids (fats) throughout the bloodstream, ensuring they reach their intended destinations for various physiological processes.
Canine ApoA, in particular, is primarily synthesized within the liver, where it undergoes an intricate series of modifications before being released into the bloodstream. This protein plays a critical role in the formation and maintenance of high-density lipoproteins (HDL), colloquially known as "good cholesterol." HDL particles, adorned with Canine ApoA, serve as the body's lipid transport vehicles, undertaking a mission vital to a dog's well-being: the management of cholesterol and other lipids.
In its role as an HDL constituent, Canine ApoA acts as both a structural framework and a functional facilitator. Structurally, it provides stability to HDL particles, allowing them to effectively encapsulate and transport lipids through the bloodstream. Functionally, Canine ApoA participates in the process of reverse cholesterol transport (RCT), an elaborate mechanism that safeguards lipid homeostasis.
Reverse cholesterol transport is a remarkable biological circuit that ensures the removal of excess cholesterol from peripheral tissues, including arterial walls, and its return to the liver for reprocessing and eventual excretion. This process is of paramount importance because it counteracts the buildup of cholesterol in blood vessels, reducing the risk of atherosclerosis, a condition characterized by the narrowing and hardening of arteries.
The significance of Canine ApoA extends beyond its structural and functional roles. It holds a mirror to a dog's cardiovascular health, making it a target of intensive scientific study and clinical attention. Elevated levels of Canine ApoA have been correlated with a reduced risk of heart disease in dogs, indicating that this protein may serve as a biomarker for cardiac health.
Additionally, Canine ApoA is entwined with the broader landscape of lipid metabolism. Disorders in lipid metabolism can manifest as hyperlipidemia, a condition marked by abnormally high levels of lipids in the bloodstream. Monitoring Canine ApoA levels can aid veterinarians in diagnosing such conditions and crafting tailored treatment plans.
Furthermore, certain dog breeds are genetically predisposed to cardiovascular issues, and Canine ApoA measurements can provide valuable insights into their susceptibility to heart problems. Regular monitoring allows for early intervention and the implementation of preventive measures, which are especially important in breed-specific healthcare.
In conclusion, Canine ApoA, as a multifaceted player in lipid metabolism and cardiovascular health, warrants thorough scientific exploration and clinical consideration. Its role in HDL and reverse cholesterol transport showcases its importance in maintaining lipid homeostasis and reducing the risk of cardiovascular diseases in dogs. The measurement of Canine ApoA levels not only serves as a biomarker for heart health but also empowers veterinarians and pet owners to make informed decisions about a dog's well-being.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.